{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:35:04Z","timestamp":1793450104258,"version":"4.5.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>There is growing interest in the relationship between Alzheimer\u2019s disease (AD) and diabetes mellitus (DM), and the glucagon-like peptide-1 receptor (GLP-1R) may be an important link between these two diseases. The role of GLP-1R in DM is principally to regulate glycemic control by stimulating insulin secretion, inhibiting glucagon secretion, and improving insulin signaling, thereby reducing blood glucose levels. In AD, GLP-1R attenuates the pathological features of AD through mechanisms such as anti-inflammatory effects, the reduction in amyloid-beta (A\u03b2) deposition, the promotion of A\u03b2 clearance, and improvements in insulin signaling. Notably, AD and DM share numerous pathophysiological mechanisms, most notably the disruption of insulin signaling pathways in the brain. These findings further underscore the notion that GLP-1R plays pivotal roles in both diseases. Taken together, these findings lead us to conclude that GLP-1R not only plays an important role in the treatment of DM and AD but also may serve as a bridge between these two diseases. Future research should focus on elucidating the detailed molecular mechanisms underlying the actions of GLP-1R in both diseases and exploring the development of GLP-1R agonists with dual therapeutic benefits for AD and DM. This could pave the way for innovative integrated treatment strategies to improve outcomes for patients affected by these intertwined conditions.<\/jats:p>","DOI":"10.3389\/fnagi.2025.1601602","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:34:33Z","timestamp":1753335273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["GLP-1R as a potential link between diabetes and Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Shujun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanqu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums.","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action.","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2021.09.006","article-title":"The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease.","volume":"176","author":"Barone","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease.","volume":"245","author":"Batista","year":"2018","journal-title":"J. Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"104896","DOI":"10.1016\/j.neubiorev.2022.104896","article-title":"Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions.","volume":"142","author":"Bhalla","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications.","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","article-title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease.","volume":"495","author":"Cai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Current evidence and future directions.","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.3390\/cimb45080420","article-title":"Oxidative Stress in type 2 diabetes: Impacts from pathogenesis to lifestyle modifications.","volume":"45","author":"Caturano","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","article-title":"GLP-1 programs the neurovascular landscape.","volume":"36","author":"Chen","year":"2024","journal-title":"Cell Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41580-025-00826-3","article-title":"Regulation and function of insulin and insulin-like growth factor receptor signalling.","volume":"26","author":"Choi","year":"2025","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/s1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial.","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease.","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s10787-025-01704-2","article-title":"Insulin resistance in Alzheimer\u2019s disease: Signalling mechanisms and therapeutics strategies.","volume":"38","author":"Dahiya","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.euroneuro.2014.06.008","article-title":"Type 3 diabetes is sporadic Alzheimer\u2019s disease: Mini-review.","volume":"24","author":"de la Monte","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/nu16030412","article-title":"The role of diet and gut microbiota in Alzheimer\u2019s disease.","volume":"16","author":"Dissanayaka","year":"2024","journal-title":"Nutrients"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1033479","DOI":"10.3389\/fendo.2022.1033479","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease.","volume":"13","author":"Du","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13105-022-00939-9","article-title":"Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts.","volume":"79","author":"Durak","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: Study protocol for a randomised controlled trial (ELAD study).","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"B20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","article-title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways.","volume":"22","author":"Fontanella","year":"2024","journal-title":"J. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s007020050068","article-title":"Brain insulin and insulin receptors in aging and sporadic Alzheimer\u2019s disease.","volume":"105","author":"Fr\u00f6lich","year":"1998","journal-title":"J. Neural Transm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-v","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease.","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics.","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fnagi.2019.00088","article-title":"Insulin Signaling impairment in the brain as a risk factor in Alzheimer\u2019s disease.","volume":"11","author":"H\u00f6lscher","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/ijms21051725","article-title":"Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity.","volume":"21","author":"Jantrapirom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.neuron.2017.07.010","article-title":"Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift.","volume":"95","author":"Jassam","year":"2017","journal-title":"Neuron"},{"key":"B28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s10020-023-00718-2","article-title":"Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt\/\u03b2-catenin\/NeuroD1 pathway.","volume":"29","author":"Kang","year":"2023","journal-title":"Mol. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/s1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer\u2019s disease and related disorders: Mechanisms and therapeutic approaches.","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acschemneuro.3c00384","article-title":"Modulation of the activity of the insulin-degrading enzyme by A\u03b2 peptides.","volume":"14","author":"Kemeh","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1205207","DOI":"10.3389\/fphar.2023.1205207","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: A systematic review and meta-analysis of preclinical studies.","volume":"14","author":"Kong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13195-024-01573-x","article-title":"Inflammatory proteins associated with Alzheimer\u2019s disease reduced by a GLP1 receptor agonist: A post hoc analysis of the EXSCEL randomized placebo controlled trial.","volume":"16","author":"Koychev","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3233\/adr-240053","article-title":"Causal association between type 2 diabetes mellitus and Alzheimer\u2019s disease: A two-sample mendelian randomization study.","volume":"8","author":"Li","year":"2024","journal-title":"J. Alzheimers Dis. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1438926","DOI":"10.3389\/fphar.2024.1438926","article-title":"Daphnetin modulates GLP-1R to alleviate cognitive dysfunction in diabetes: Implications for inflammation and oxidative stress.","volume":"15","author":"Liang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"697440","DOI":"10.3389\/fnmol.2021.697440","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing \u03b1-synuclein and oxidative stress.","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6813017","DOI":"10.1155\/2022\/6813017","article-title":"Semaglutide protects against 6-OHDA toxicity by enhancing autophagy and inhibiting oxidative stress.","volume":"2022","author":"Liu","year":"2022","journal-title":"Parkinsons Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes.","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3892\/ijmm.2018.3509","article-title":"GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF-\u03baB signaling pathways in streptozotocin-induced diabetic rats.","volume":"41","author":"Ma","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40478-019-0695-5","article-title":"Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord.","volume":"7","author":"Macdonald","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice.","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/jneurosci.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease.","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1400544","DOI":"10.3389\/fnagi.2024.1400544","article-title":"Neurotoxic \u03b2-amyloid oligomers cause mitochondrial dysfunction-the trigger for PANoptosis in neurons.","volume":"16","author":"Meng","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/0019-5545.44908","article-title":"Neurobiology of Alzheimer\u2019s disease.","volume":"51","author":"Mohandas","year":"2009","journal-title":"Indian J. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"105510","DOI":"10.1016\/j.nbd.2021.105510","article-title":"Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer\u2019s disease.","volume":"159","author":"Ochiai","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e2408581","DOI":"10.1002\/smll.202408581","article-title":"The mitochondria-targeted micelle inhibits Alzheimer\u2019s disease progression by alleviating neuronal mitochondrial dysfunction and neuroinflammation.","volume":"21","author":"Qian","year":"2025","journal-title":"Small"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.7150\/ijbs.68974","article-title":"Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury.","volume":"18","author":"Qian","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.molmed.2024.10.010","article-title":"Advancements and challenges in mouse models of Alzheimer\u2019s disease.","volume":"30","author":"Qian","year":"2024","journal-title":"Trends Mol. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review.","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"20631","DOI":"10.1074\/jbc.271.34.20631","article-title":"Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer\u2019s disease.","volume":"271","author":"Roher","year":"1996","journal-title":"J. Biol. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/nmm:1:1:1","article-title":"Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer\u2019s disease.","volume":"1","author":"Sambamurti","year":"2002","journal-title":"Neuromol. Med."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/jci168553","article-title":"Tau pathology in neurodegenerative disease: Disease mechanisms and therapeutic avenues.","volume":"133","author":"Samudra","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"151016","DOI":"10.1016\/j.bbrc.2024.151016","article-title":"GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid \u03b2 clearance in a mouse model of Alzheimer\u2019s disease.","volume":"741","author":"Sasaki","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease.","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41574-021-00498-x","article-title":"Brain insulin signalling in metabolic homeostasis and disease.","volume":"17","author":"Scherer","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e54083","DOI":"10.7554\/eLife.54083","article-title":"Fibrillar A\u03b2 triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.","volume":"9","author":"Sebastian Monasor","year":"2020","journal-title":"Elife"},{"key":"B56","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.3390\/ijms22189987","article-title":"Insulin and insulin resistance in Alzheimer\u2019s disease.","volume":"22","author":"S\u00eadzikowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.04.018","article-title":"Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R\/Akt\/GSK3\u03b2 signaling.","volume":"153","author":"Shu","year":"2019","journal-title":"Neuropharmacology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.3390\/ijms23179655","article-title":"cAMP\/PKA signaling modulates mitochondrial supercomplex organization.","volume":"23","author":"Signorile","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/jad-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2013is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jalz.2013.12.007","article-title":"The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease.","volume":"10","author":"Talbot","year":"2014","journal-title":"Alzheimers Dement."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function.","volume":"31","author":"Timper","year":"2020","journal-title":"Cell. Metab."},{"key":"B62","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cell.2021.12.041","article-title":"Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.","volume":"185","author":"Tracy","year":"2022","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-025-04018-w","article-title":"The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: Evidence from a network meta-analysis.","volume":"23","author":"Tseng","year":"2025","journal-title":"BMC Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/ph18050614","article-title":"Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of Alzheimer\u2019s disease.","volume":"18","author":"Urkon","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3892\/etm.2016.3742","article-title":"Exendin-4 antagonizes A\u03b21-42-induced attenuation of spatial learning and memory ability.","volume":"12","author":"Wang","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2174\/1386207325666220726163514","article-title":"Dulaglutide alleviates Alzheimer\u2019s disease by regulating microglial polarization and neurogenic activity.","volume":"28","author":"Wang","year":"2025","journal-title":"Comb. Chem. High. Throughput Screen"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e10505","DOI":"10.1002\/btm2.10505","article-title":"Neuroprotective effect of engineered Clostridiumbutyricum-pMTL007-GLP-1 on Parkinson\u2019s disease mice models via promoting mitophagy.","volume":"8","author":"Wang","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"622737","DOI":"10.3389\/fendo.2021.622737","article-title":"Exenatide attenuates obesity-induced mitochondrial dysfunction by activating SIRT1 in renal tubular cells.","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"109716","DOI":"10.1016\/j.neuropharm.2023.109716","article-title":"Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway.","volume":"240","author":"Wang","year":"2023","journal-title":"Neuropharmacology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"114578","DOI":"10.1016\/j.bcp.2021.114578","article-title":"GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer\u2019s disease by regulating mitochondrial dysfunction via the cAMP\/PKA pathway.","volume":"188","author":"Xie","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"171271","DOI":"10.1016\/j.peptides.2024.171271","article-title":"Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice.","volume":"179","author":"Yang","year":"2024","journal-title":"Peptides"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.3390\/cimb44120421","article-title":"The strategies for treating \u201cAlzheimer\u2019s disease\u201d: Insulin signaling may be a feasible target.","volume":"44","author":"You","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"16680","DOI":"10.1038\/s41598-024-66998-8","article-title":"Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.","volume":"14","author":"Yuan","year":"2024","journal-title":"Sci. Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"111529","DOI":"10.1016\/j.mce.2021.111529","article-title":"Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer\u2019s disease by suppressing NLRP2 activation in astrocytes.","volume":"542","author":"Zhang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13098-018-0392-8","article-title":"Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes.","volume":"10","author":"Zhang","year":"2018","journal-title":"Diabetol. Metab. Syndr."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1112363","DOI":"10.3389\/fendo.2023.1112363","article-title":"The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"101457","DOI":"10.1016\/j.nantod.2022.101457","article-title":"Regulation of neuroinflammation with GLP-1 receptor targeting nanostructures to alleviate Alzheimer\u2019s symptoms in the disease models.","volume":"44","author":"Zhao","year":"2022","journal-title":"Nano Today"},{"key":"B79","doi-asserted-by":"publisher","first-page":"101180","DOI":"10.1016\/j.molmet.2021.101180","article-title":"GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease.","volume":"47","author":"Zheng","year":"2021","journal-title":"Mol. Metab."},{"key":"B80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13205-021-02738-3","article-title":"Role of insulin receptor substance-1 modulating PI3K\/Akt insulin signaling pathway in Alzheimer\u2019s disease.","volume":"11","author":"Zheng","year":"2021","journal-title":"3 Biotech"},{"key":"B81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","article-title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2.","volume":"511","author":"Zhou","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1601602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:34:34Z","timestamp":1753335274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1601602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":81,"alternative-id":["10.3389\/fnagi.2025.1601602"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2025.1601602","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1601602"}}